Guangxi Wuzhou Zhongheng Group (600252.SH) subsidiary obtains drug supplemental application approval notice.

Guangxi Wuzhou Zhongheng Group (600252.SH) announced recently that its subsidiary, Chongqing Lummy Pharmaceutical Co., Ltd. (hereinafter referred to as "Chongqing Lummy Pharmaceutical"), has received approval from the National Medical Products Administration for the production of two specifications of naloxone hydrochloride injection: 1ml:1mg and 2ml:2mg. Naloxone hydrochloride injection is an opioid receptor antagonist drug, with the following indications: used for reversing respiratory depression caused by opioid drugs in postoperative anesthesia; used to completely or partially reverse respiratory depression caused by opioid drug overdose; used to rescue acute ethanol poisoning; used for the diagnosis of acute opioid drug overdose.